Antiviral Drug Discovery To Address the COVID-19 Pandemic-Reference-Cited by-同舟云学术

Antiviral Drug Discovery To Address the COVID-19 Pandemic

Published:2020-10-27 Issue:5 Volume:11 Page:
ISSN:2161-2129
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Richman Douglas D.¹^ORCID

Affiliation:

1. University of California San Diego, Distinguished Professor of Pathology and Medicine (Active Emeritus), Director, The HIV Institute, Co-Director, San Diego Center for AIDS Research, Florence Seeley Riford Chair in AIDS Research (Emeritus), La Jolla, California, USA

Abstract

The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M pro ) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.02134-20

Reference12 articles.

1. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection

2. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

3. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

4. Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

5. Good S Westover J Jung KH La Colla P Collu G Moussa A Canard B Sommadossi J-P. 2020. AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2 the virus responsible for the COVID-19 pandemic. bioRxiv doi:10.1101/2020.08.11.242834.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Repurposing: Challenges and Successes in the Treatment of SARS-CoV-2;Drug Repurposing - Advances, Scopes and Opportunities in Drug Discovery;2023-06-07

2. Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment;European Journal of Medicinal Chemistry Reports;2021-12

3. The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses;Microorganisms;2021-08-14

4. Perspectives on Antiviral Drugs Development in the Treatment of COVID-19;Acta Biologica Marisiensis;2021-06-01

5. Existing Drugs Considered as Promising in COVID-19 Therapy;International Journal of Molecular Sciences;2021-05-21